Explore the latest news from Khondrion and its team.
NIJMEGEN, the Netherlands – 1 June 2022: Khondrion (or the “Company”), a clinical stage biopharmaceutical company discovering and developing...
NIJMEGEN, the Netherlands – 10 January 2022: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting...
Enabling continued treatment in 52-week multi-centre study for patients who have completed ongoing KHENERGYZE Phase IIb study investigating...
NIJMEGEN, the Netherlands – 14 October 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
NIJMEGEN, the Netherlands – 26 August 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces the...
Cognition is an important function of the brain so we can gain knowledge and understanding. These mental processes include thinking, knowing,...
Classic MELAS syndrome (Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes), MIDD (maternally inherited diabetes mellitus...
1. Tell us all about your career before joining Khondrion I studied pharmacology and molecular biology at the University of Strasbourg in France,...
Chief Executive Officer of Khondrion, Prof. Dr. Jan Smeitink, reflects on the Mitochondrial Medicine conference held from 11-13 December 2019 at the...
Members of the Khondrion team will be attending Mitochondrial Medicine 2019 on 11-13 December 2019. The event will bring together...
Reflections on SSIEM annual symposium 2019 – Building Bridges Chief Executive Officer of Khondrion, Prof. Dr. Jan Smeitink, reflects on the...
